IL201564A - 6s 70p kinase inhibitors - Google Patents

6s 70p kinase inhibitors

Info

Publication number
IL201564A
IL201564A IL201564A IL20156409A IL201564A IL 201564 A IL201564 A IL 201564A IL 201564 A IL201564 A IL 201564A IL 20156409 A IL20156409 A IL 20156409A IL 201564 A IL201564 A IL 201564A
Authority
IL
Israel
Prior art keywords
phenyl
add
compound
imidazol
trifluoromethyl
Prior art date
Application number
IL201564A
Other languages
English (en)
Hebrew (he)
Other versions
IL201564A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL201564A0 publication Critical patent/IL201564A0/en
Publication of IL201564A publication Critical patent/IL201564A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL201564A 2007-05-11 2009-10-15 6s 70p kinase inhibitors IL201564A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91733107P 2007-05-11 2007-05-11
PCT/US2008/062143 WO2008140947A1 (en) 2007-05-11 2008-05-01 P70 s6 kinase inhibitors

Publications (2)

Publication Number Publication Date
IL201564A0 IL201564A0 (en) 2010-05-31
IL201564A true IL201564A (en) 2014-08-31

Family

ID=39765082

Family Applications (1)

Application Number Title Priority Date Filing Date
IL201564A IL201564A (en) 2007-05-11 2009-10-15 6s 70p kinase inhibitors

Country Status (33)

Country Link
US (2) US8093383B2 (cg-RX-API-DMAC7.html)
EP (1) EP2148880B1 (cg-RX-API-DMAC7.html)
JP (1) JP5503532B2 (cg-RX-API-DMAC7.html)
KR (1) KR101088219B1 (cg-RX-API-DMAC7.html)
CN (1) CN101679439B (cg-RX-API-DMAC7.html)
AR (1) AR066344A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008251692B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0811212A2 (cg-RX-API-DMAC7.html)
CA (1) CA2687265C (cg-RX-API-DMAC7.html)
CL (1) CL2008001230A1 (cg-RX-API-DMAC7.html)
CO (1) CO6241109A2 (cg-RX-API-DMAC7.html)
CR (1) CR11106A (cg-RX-API-DMAC7.html)
DK (1) DK2148880T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2009000257A (cg-RX-API-DMAC7.html)
EA (1) EA016445B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP099721A (cg-RX-API-DMAC7.html)
ES (1) ES2483726T3 (cg-RX-API-DMAC7.html)
GT (1) GT200900292A (cg-RX-API-DMAC7.html)
HR (1) HRP20140611T1 (cg-RX-API-DMAC7.html)
IL (1) IL201564A (cg-RX-API-DMAC7.html)
MA (1) MA31433B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009012075A (cg-RX-API-DMAC7.html)
MY (1) MY154898A (cg-RX-API-DMAC7.html)
NZ (1) NZ580423A (cg-RX-API-DMAC7.html)
PE (1) PE20090887A1 (cg-RX-API-DMAC7.html)
PL (1) PL2148880T3 (cg-RX-API-DMAC7.html)
PT (1) PT2148880E (cg-RX-API-DMAC7.html)
RS (1) RS53451B (cg-RX-API-DMAC7.html)
SI (1) SI2148880T1 (cg-RX-API-DMAC7.html)
TN (1) TN2009000446A1 (cg-RX-API-DMAC7.html)
TW (1) TWI423805B (cg-RX-API-DMAC7.html)
UA (1) UA99284C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008140947A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
WO2010019762A1 (en) * 2008-08-13 2010-02-18 Jenrin Discovery Purine compounds as cannabinoid receptor blockers
CA2743242A1 (en) * 2008-11-11 2010-05-20 Eli Lilly And Company P70 s6 kinase inhibitor and mtor inhibitor combination therapy
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
CA2743295A1 (en) 2008-11-11 2010-05-20 Eli Lilly And Company P70 s6 kinase inhibitor and egfr inhibitor combination therapy
HRP20141239T1 (xx) 2009-02-11 2015-03-13 Merck Patent Gmbh Novi amino azaheterocikliäśki karboksamidi
SG178273A1 (en) 2009-08-07 2012-03-29 Merck Patent Gmbh Novel azaheterocyclic compounds
JP5581390B2 (ja) * 2009-10-23 2014-08-27 イーライ リリー アンド カンパニー Ａｋｔ阻害剤
SG183155A1 (en) 2010-02-03 2012-09-27 Signal Pharm Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
CA2803387C (en) 2010-07-29 2017-12-05 Bayard R. Huck Cyclic amine azaheterocyclic carboxamides
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
US8946247B2 (en) 2010-11-24 2015-02-03 Merck Patent Gmbh Quinazoline carboxamide azetidines
HUE034979T2 (en) 2011-09-12 2018-05-02 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
MX346095B (es) * 2011-09-12 2017-03-07 Merck Patent Gmbh Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
MX2015002887A (es) * 2012-09-06 2015-07-06 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP3299362B1 (en) * 2012-11-16 2020-04-22 Merck Patent GmbH Imidazol-piperidinyl derivatives as modulators of kinase activity
US9580443B2 (en) 2012-11-16 2017-02-28 Merck Patent Gmbh Heterocyclic derivatives as modulators of kinase activity
PE20151782A1 (es) 2012-11-29 2015-12-02 Merck Patent Gmbh Derivados de azaquinolin-carboxamida
ES2746756T3 (es) * 2013-03-11 2020-03-06 Merck Patent Gmbh Derivados de 6-[4-(1H-imidazol-2-il)piperidin-1-il]pirimidin-4-amina como moduladores de la actividad cinasa
KR102271344B1 (ko) 2013-04-17 2021-07-01 시그날 파마소티칼 엘엘씨 디하이드로피라지노-피라진을 사용한 암의 치료
ES2744198T3 (es) 2013-04-17 2020-02-24 Signal Pharm Llc Formulaciones farmacéuticas, procesos, formas sólidas y procedimientos de uso relacionados con 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3, 4 dihidropirazino[2,3-b]pirazin-2(1H)-ona
JP6382947B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー 前立腺癌を治療するためのジヒドロピラジノ−ピラジン化合物及びアンドロゲン受容体アンタゴニストを含む組合せ療法
CN105392499B (zh) 2013-04-17 2018-07-24 西格诺药品有限公司 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
KR102240356B1 (ko) 2013-04-17 2021-04-14 시그날 파마소티칼 엘엘씨 Ｔｏｒ 키나제 억제제와 5-치환된 퀴나졸리논 화합물을 포함하는 암 치료용 조합 요법
CN105377260B (zh) 2013-04-17 2020-06-12 西格诺药品有限公司 二氢吡嗪并-吡嗪类化合物在制备治疗癌症的药物中的应用
BR112015026021A2 (pt) 2013-04-17 2017-07-25 Signal Pharm Llc terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
WO2014193912A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN106456752B (zh) 2014-04-03 2020-11-20 默克专利股份公司 癌症治疗剂的组合
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2016040078A1 (en) * 2014-09-10 2016-03-17 Eli Lilly And Company Substituted phenyl imidazolyl piperidyl compounds as p70s6k1 inhibitors
WO2016164641A1 (en) 2015-04-08 2016-10-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
EA202090103A1 (ru) 2017-06-22 2020-04-24 Селджин Корпорейшн Лечение гепатоцеллюлярной карциномы, которая характеризуется вирусной инфекцией гепатита b
US20240024324A1 (en) 2020-11-16 2024-01-25 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
JP5213229B2 (ja) * 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
CA2590961C (en) 2004-12-28 2013-11-26 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2007125310A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
CA2687265C (en) 2012-12-04
UA99284C2 (ru) 2012-08-10
AU2008251692B2 (en) 2012-10-11
EP2148880A1 (en) 2010-02-03
TWI423805B (zh) 2014-01-21
PE20090887A1 (es) 2009-07-13
IL201564A0 (en) 2010-05-31
HK1140767A1 (en) 2010-10-22
RS53451B (sr) 2014-12-31
AU2008251692A1 (en) 2008-11-20
TW200848053A (en) 2008-12-16
CO6241109A2 (es) 2011-01-20
SI2148880T1 (sl) 2014-07-31
GT200900292A (es) 2011-06-24
AR066344A1 (es) 2009-08-12
DK2148880T3 (da) 2014-06-16
CR11106A (es) 2010-04-12
CN101679439A (zh) 2010-03-24
CL2008001230A1 (es) 2009-05-22
US8093383B2 (en) 2012-01-10
PL2148880T3 (pl) 2014-10-31
DOP2009000257A (es) 2010-03-31
NZ580423A (en) 2012-02-24
EP2148880B1 (en) 2014-05-28
PT2148880E (pt) 2014-08-28
JP5503532B2 (ja) 2014-05-28
US20090163714A1 (en) 2009-06-25
MA31433B1 (fr) 2010-06-01
BRPI0811212A2 (pt) 2014-10-29
CN101679439B (zh) 2013-09-11
WO2008140947A1 (en) 2008-11-20
KR20100005710A (ko) 2010-01-15
EA200971051A1 (ru) 2010-06-30
CA2687265A1 (en) 2008-11-20
ECSP099721A (es) 2009-12-28
MX2009012075A (es) 2009-11-19
TN2009000446A1 (en) 2011-03-31
MY154898A (en) 2015-08-28
US20120071490A1 (en) 2012-03-22
KR101088219B1 (ko) 2011-11-30
ES2483726T3 (es) 2014-08-07
HRP20140611T1 (hr) 2014-08-15
EA016445B1 (ru) 2012-05-30
JP2010526814A (ja) 2010-08-05

Similar Documents

Publication Publication Date Title
CA2687265C (en) P70 s6 kinase inhibitors
ES2391704T3 (es) Inhibidores de cinasa AKT y P70 S6
AU2010310786B2 (en) AKT inhibitors
CA3189912A1 (en) Bicyclic compounds, compositions and use thereof
EP2742046A1 (en) PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE
CA3122136A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
JP2023062074A (ja) Ｂ－ｒａｆキナーゼ阻害物質の結晶塩
IL294214A (en) Cyclic compounds and methods of using them
HK1140767B (en) P70 s6 kinase inhibitors
HK1158203B (en) Akt and p70 s6 kinase inhibitors

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees
KB Patent renewed
NP Permission for amending the patent specification granted (section 66, patents law 1967)
MM9K Patent not in force due to non-payment of renewal fees